Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature.
Idiopathic hypertrophic cranial pachymeningitis (IHCP) is a rare clinical entity, characterized by a chronic inflammation causing thickening of the dura. Adequate therapeutic management is still a matter of debate. We present a patient with an IHCP, non-responsive to corticotherapy. Oral methotrexate was introduced (12.5 mg weekly) and total remission was observed after 6 weeks, both clinically and after neuro-imaging. We conclude that methotrexate can be effective and a therapeutical option in patients with IHCP who are resistant to corticotherapy or present major side-effects of chronic corticosteroids use.
Bosman
T
T
Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands, T.Bosman@LUMC.nl
Simonin
C
C
Launay
D
D
Caron
S
S
Destée
A
A
Defebvre
L
L
D000284:Administration, Oral; D004388:Dura Mater / Q000473:pathology*; D006801:Humans; D006984:Hypertrophy; D008279:Magnetic Resonance Imaging; D008297:Male; D008581:Meningitis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged
D008727:Methotrexate